MedTrace Logo

TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma

NCT01039025 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-11-07

No results posted yet for this study

Summary

To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients with Multiple Myeloma.

Conditions

Interventions

DRUG

Topotecan

After stem cells are collected, Topotecan 3.5 mg/m\^2 intravenously given over 30 minutes on Days 1 - 5.

DRUG

Cyclophosphamide

After stem cells are collected, Cyclophosphamide 1 g/m\^2/day intravenously given over 2 hours on Days 1 - 3.

DRUG

Melphalan

After stem cells are collected, Melphalan 70 mg/m\^2/day intravenously given on Days 4 and 5.

OTHER

Peripheral Blood Stem Cells

On Day 7, some or all of the stem cells will be reinfused.

Sponsors & Collaborators

  • SmithKline Beecham

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Michelle Donato, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-18
Primary Completion
2006-05-19
Completion
2006-05-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01039025 on ClinicalTrials.gov